Výsledky vyhledávání - Andreas Pinter

Upřesnit hledání
  1. 1
    Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

    Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients Autor Sascha Gerdes, Andreas Pinter, C. Papavassilis, M. Reinhardt

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Clinical Course and Characteristics of Generalized Pustular Psoriasis

    Clinical Course and Characteristics of Generalized Pustular Psoriasis Autor Siew Eng Choon, Alexander A. Navarini, Andreas Pinter

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

    A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with modera... Autor Kristian Reich, Matthias Augustin, Diamant Thaçi, Andreas Pinter, A. Leutz, Carsten Henneges, Emma Schneider, Alexander Schacht, M. Dossenbach, U. Mrowietz

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study

    Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study Autor Christian Kromer, Emilia Loewe, Marthe‐Lisa Schaarschmidt, Andreas Pinter, Sascha Gerdes, Raphael M. Herr, Sietske Poortinga, Rotraut Moessner, Dagmar Wilsmann‐Theis

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

    IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants... Autor Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz‐Elías, Holger Bartz, F. Taut, Kristian Reich

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Autor Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis

    Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis Autor Amy S. Paller, Andreas Pinter, Lara Wine Lee, Roland Aschoff, Jacek Zdybski, Christina Schnopp, Amy Praestgaard, Ashish Bansal, Brad Shumel, Randy Prescilla, Mike Bastian

    Vydáno 2024
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

    Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pi... Autor Ulrich Mrowietz, A. David Burden, Andreas Pinter, Kristian Reich, Knut Schäkel, Patrick Baum, Yakov Datsenko, Hongjie Deng, Steven J. Padula, Christian Thoma, Robert Bissonnette

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-R... Autor Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, C.E.M. Griffiths

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the <scp>STEPIn</scp> study

    Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the <scp>STEPIn</sc... Autor Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Külli Kingo, R. Rivera, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Frueh, Piotr Jagiello

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study

    Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study Autor Kristian Reich, Andreas Pinter, J.‐P. Lacour, Carlos Ferrándiz, Giuseppe Micali, Lars E. French, Mark Lomaga, Yves Dutronc, Carsten Henneges, Stefan Wilhelm, Susanne Hartz, C. Paul

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*

    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized contro... Autor Matthias Augustin, Kristian Reich, Paul S. Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, R. You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

    Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA... Autor Jonathan I. Silverberg, David N. Adam, Matthew Zirwas, Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew Pink, Andrea Chiricozzi, S. Barbarot, Thomas Mark, Ann-Marie Tindberg, Stephan Weidinger

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

    Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus Autor Jonathan I. Silverberg, Andreas Pinter, Grażyna Pulka, Yves Poulin, Jean‐David Bouaziz, Andreas Wollenberg, Dédée F. Murrell, Andrew Alexis, Lisa Lindsey, Faiz Ahmad, Christophe Piketty, Alan Clucas

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase <scp>III</scp> study

    Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase <scp>III</scp> study Autor Diamant Thaçi, Kim Papp, Danielle Marcoux, Lisa Weibel, Andreas Pinter, Pierre‐Dominique Ghislain, Ian Landells, Peter H. Hoeger, Kristina Unnebrink, M.M.B. Seyger, David Williams, Simone Rubant, Sandra Philipp

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase <scp>IIIb</scp> randomized, double‐blind, parallel‐group, <scp>GUIDE</scp> study

    Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase... Autor Knut Schäkel, Kristian Reich, K. Asadullah, Andreas Pinter, D. Jullien, Peter Weisenseel, C. Paul, Mario Gomez, Sven Wegner, Yvonne Personke, Fabian Kreimendahl, Yanqing Chen, Julianty Angsana, Monica Leung, Kilian Eyerich

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>)

    Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp... Autor Andreas Pinter, L. Puig, Knut Schäkel, Adam Reich, Shirin Zaheri, Antonio Costanzo, Tsen‐Fang Tsai, Saxon D. Smith, Charles Lynde, Alan Brnabic, Catherine Reed, Julie Hill, Christopher Schuster, Elisabeth Riedl, C. Paul

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks

    Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Autor Esther von Stebut, Kristian Reich, Diamant Thaçi, Wolfgang Köenig, Andreas Pinter, Andreas Körber, Tienush Rassaf, Ari Waisman, Venkatesh Mani, Denise P. Yates, Jennifer Frueh, Christian Sieder, Nima Melzer, Nehal N. Mehta, Tommaso Gori

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study

    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placeb... Autor Joseph F. Merola, Albert S. Chiou, Emmanuel During, Antonio Costanzo, Peter Foley, Amani Alfalasi, S. Gogate, Andreas Pinter, Roni P. Dodiuk‐Gad, Dagmar Simon, M. Tauber, Richard Weller, J Rodríguez, Marius Ardeleanu, Jiangming Wu, Zafer E. Ozturk

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )

    Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <... Autor Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños, Jerry Bagel, Andreas Pinter, Jennifer Clay Cather, Stuart Keller, Claudia Rodriguez Capriles, Renata Gontijo Lima, Gaia Gallo, Carol Little, Emily Edson‐Heredia, Lü Li, W. Xu, Kim Papp

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: